Lyell Immunopharma, Inc.LYELNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank17
3Y CAGR-27.3%
5Y CAGR-0.8%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-27.3%/yr
Annual compound
5Y CAGR
-0.8%/yr
Recent deceleration
Percentile
P17
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$45.13M-13.3%
2024$52.04M-22.3%
2023$66.98M-42.9%
2022$117.31M+31.7%
2021$89.06M+90.0%
2020$46.88M+19.7%
2019$39.15M-